Cost-Effectiveness Evaluation of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Study

• Published in: Diabetes therapy 2022-04, Vol.13 (4), p.693-708
• Main Authors: Mounié, Michael, Costa, Nadège, Gourdy, Pierre, Latorre, Christelle, Schirr-Bonnans, Solène, Lagarrigue, Jean-Marc, Roussel, Henri, Martini, Jacques, Buisson, Jean-Christophe, Chauchard, Marie-Christine, Delaunay, Jacqueline, Taoui, Soumia, Poncet, Marie-France, Cosma, Valeria, Lablanche, Sandrine, Coustols-Valat, Magali, Chaillous, Lucie, Thivolet, Charles, Sanz, Caroline, Penfornis, Alfred, Lepage, Benoît, Colineaux, Hélène, Hanaire, Hélène, Molinier, Laurent, Turnin, Marie-Christine
• Format: Article
• Language: English
• Subjects: Cardiology; Care and treatment; Cost analysis; Cost benefit analysis; Diabetes; Disease management; Endocrinology; Evaluation; Glucose monitoring; Internal Medicine; Life Sciences; Lifestyles; Medical care; Medicine; Medicine & Public Health; NCT; NCT01955031; Original Research; Patient education; Patient monitoring; Patient outcomes; Quality management; Telemedicine; Type 2 diabetes
• ISSN: 1869-6953; 1869-6961
• DOI: 10.1007/s13300-022-01207-1

Introduction Telemedicine programs using health technological innovation to remotely monitor the lifestyles of patients with type 2 diabetes (T2D) can improve glycaemic control and thus reduce the incidence of complications as well as management costs. In this context, an assessment was made of the 1-year and 2-year cost-effectiveness of the EDUC@DOM telemonitoring and tele-education program. Methods The EDUC@DOM study was a multicentre randomized controlled trial conducted between 2013 and 2017 that compared a telemonitoring group (TMG) to a control group (CG) merged with health insurance databases to extract economic data on resource consumption. Economic analysis was performed from the payer perspective, and direct costs and indirect costs were considered. The clinical outcome used was the intergroup change in glycated haemoglobin (HbA1c) levels from baseline. Missing economic data were imputed using multiple imputation, and fitted values from a generalized linear mixed model were used to calculate the incremental cost-effectiveness ratio (ICER). Bootstrapped 95% confidence ellipses were drawn in the cost-effectiveness plan. Results The main analysis included data from 256 patients: 126 in the TMG and 130 in the CG. Incremental costs over 1 and 2 years were equal to €2129 and €5101, respectively, in favour of the TMG. Once imputed and adjusted for confounding factors, the TMG trends to a 21% cost decrease over 1 and 2 years of follow-up (0.79 [0.58; 1.08], p  = 0.1452 and 0.79 [0.61; 1.03], p  = 0.0879, respectively). The EDUC@DOM program led to a €1334 cost saving and a 0.17 decrease in HbA1c over 1 year and a €3144 cost saving and a 0.14 decrease in HbA1c over 2 years. According to the confidence ellipse, EDUC@DOM was a cost-effective strategy. Conclusion This study provides additional economic information on telemonitoring and tele-education programs to enhance their acceptance and promote their use. In the light of this work, the EDUC@DOM program is a cost-saving strategy in T2D management. Trial registration This trial was registered in the Clinical Trials Database on 27 September 2013 under no. NCT01955031 and bears ID-RCB no. 2013-A00391-44.